AIO-Studien-gGmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
127
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (111 trials with phase data)• Click on a phase to view related trials
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
- Conditions
- Squamous Cell Carcinoma of the HypopharynxSquamous Cell Carcinoma of the LarynxSquamous Cell Carcinoma of the OropharynxSquamous Cell Carcinoma of the Oral Cavity
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06380686
- Locations
- 🇩🇪
Onkologie/Studienzentrum am Raschplatz GbR, Hannover, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 3000
- Registration Number
- NCT05701150
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Baden-Württemberg, Germany
🇩🇪Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Baden-Württemberg, Germany
🇩🇪Klinikum der Universität München, München, Bayern, Germany
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
- Conditions
- Colon CancerBRAF V600 MutationLocalized CancerBRAF V600EColorectal Cancer
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 48
- Registration Number
- NCT05510895
- Locations
- 🇩🇪
Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, Germany
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
- Conditions
- NSCLC Stage IV
- Interventions
- Drug: platinum-based chemotherapy (SoC)
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- AIO-Studien-gGmbH
- Registration Number
- NCT05383001
- Locations
- 🇩🇪
Asklepios Fachkliniken München-Gauting, Gauting, Germany
D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
- Conditions
- Chemo-refractory Colorectal Carcinoma
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 18
- Registration Number
- NCT05212012
- Locations
- 🇩🇪
Universitätsklinikum Hamburg Eppendorf - II. Med., Hamburg, Germany
🇩🇪Universitätsklinikum Ulm - Innere Med. I, Ulm, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next